Who are I-123 mIBG's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DEXTROAMPHETAMINE, SPN-812 (600mg, QD), fluoxetine + Amfebutamone, Active bupropion + counseling, Paracetamol-Tramadol, Tramadol HCl/acetaminophen Extended Release.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/i-123-mibg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

I-123 mIBG — Competitive Intelligence Brief

I-123 mIBG (I-123 mIBG) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radioligand. Area: Oncology.

phase 2 Radioligand Norepinephrine transporter Oncology Small molecule Live · refreshed every 30 min

Target snapshot

I-123 mIBG (I-123 mIBG) — GE Healthcare. I-123 mIBG binds to norepinephrine transporters

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
I-123 mIBG TARGET	I-123 mIBG	GE Healthcare	phase 2	Radioligand	Norepinephrine transporter
DEXTROAMPHETAMINE	DEXTROAMPHETAMINE		marketed	Central nervous system stimulant	Dopamine transporter (DAT), Norepinephrine transporter (NET)	1955-01-01
SPN-812 (600mg, QD)	SPN-812 (600mg, QD)	Supernus Pharmaceuticals, Inc.	marketed	Selective norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)
fluoxetine + Amfebutamone	fluoxetine + Amfebutamone	Shanghai Mental Health Center	marketed	SSRI + NDRI combination antidepressant	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT)
Active bupropion + counseling	Active bupropion + counseling	University of Wisconsin, Madison	marketed	Antidepressant (dopamine-norepinephrine reuptake inhibitor)	Dopamine transporter (DAT), Norepinephrine transporter (NET)
Paracetamol-Tramadol	Paracetamol-Tramadol	Astes	marketed	Analgesic combination (non-opioid + opioid)	Cyclooxygenase (COX), opioid receptors (μ, δ, κ), norepinephrine transporter, serotonin transporter
Tramadol HCl/acetaminophen Extended Release	Tramadol HCl/acetaminophen Extended Release	Janssen Korea, Ltd., Korea	marketed	Opioid analgesic combination with NSAID alternative	Mu-opioid receptor; norepinephrine transporter; serotonin transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-10-24 — DEXTROAMPHETAMINE · 9456993 · Formulation · US
2033-10-24 — DEXTROAMPHETAMINE · 9474722 · Formulation · US
2042-01-06 — DEXTROAMPHETAMINE · 11559501 · Formulation · US

Sponsor landscape (Radioligand class)

Clarity Pharmaceuticals Ltd · 1 drug in this class
GE Healthcare · 1 drug in this class
Queen's Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). I-123 mIBG — Competitive Intelligence Brief. https://druglandscape.com/ci/i-123-mibg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab